Abstract
A rare case of severe acute hepatitis A complicated by pure red cell aplasia (PRCA) is reported. A 60-year-old man with jaundice and hepatomegaly was diagnosed as having acute hepatitis A by positive IgM anti-hepatitis A antibody (anti-HAV). Severe anemia rapidly developed 3 weeks after admission, and the patient was diagnosed with PRCA by both bone marrow smears and crythrocyte survival study. The anemia was transient and bone marrow recovered within 1 week. However, concomitant with bone marrow recovery, the hepatitis worsened. He became drowsy and disoriented and severe jaundice, ascites, prolonged prothrombin time, increased transaminase levels, and abnormal electroencephalogram (EEG) were exhibited. Plasma exchange transfusion and glucagon-insulin (GI) therapy improved the consciousness level, but bilirubin, transaminase levels, and IgM anti-HAV titer remained high. Intravenous administration of lipophilized prostaglandin E1 (lipo-PGE1) was added to the GI therapy. Bilirubin and transaminase levels were normalized in the 8th week after the initiation of this combination therapy (17 weeks after admission). The combined use of lipo-PGE1 with plasma exchange and GI therapy appeared to be useful for the prolonged severe hepatitis in this patient.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Tanikawa H. Clinical aspects of hepatitis A. Proceedings of 12th Inuyama symposium, Aichi, Japan, Aug 1982. Tokyo: Chugai igakusha, 1982; 53.
Tomiyama J, Kudou H, Adachi Y, et al. A case of pure red cell aplasia after hepatitis A. Jpn J Clin Hematol 1987;28:2187–2192.
Sugihara M, Murao K, Kakiuchi T, et al. A case in which complication of transient pure red cell aplasia was suspected in the course of acute hepatitis A (abstract). J Jpn Society Intern Med 1987;76:158–159.
Fujisaki J, Suga K, Ozaki I, et al. A case which showed marked anemia considered as pure red cell aplasia complicating acute hepatitis A (abstract). J Jpn Society Intern Med 1987;76:131–132.
Gundersen SG, Bjoerneklett A, Bruun JN. Severe erhthroblastopenia and hemolytic anemia during a hepatitis A infection. Scand J Infect Dis 1989;21:225–228.
Touri R, Nishimura H, Nakamura K, et al. A case of acute hepatitis A complicating acute pure red cell aplasia. J Jpn Society Intern Med 1990;79:111–112.
Tomonari A, Hirai K, Aoki H, et al. Pure red cell aplasia and pseudo thrombocytopenia associated with hepatitis A (in Japanese with English abstract). Jpn J Clin Hematol 1991;32:147–151.
Fujioka H, Hamaguchi K, Ogasawara M, et al. A case of acute hepatitis A complicating acute pure red cell aplasia (in Japanese with English abstract). Acta Hepatol Jap 1991;32:650–655.
Abe K, Utoh H, Yamamoto Y, et al. A case of acute hepatitis type A showing simultaneous occurrence of pure red cell aplasia and hemolytic anemia (in Japanese) Jpn J Gastroenterol 1991;88:1500–1503.
Sears DA, George JN, Gold MS. Transient red blood cell aplasia in association with viral hepatitis. Arch Intern Med 1975;135:1585–1589.
Pezzimenti JF, Lindenbaum J. Megaloblastic anemia associated with erythroid hypoplasia. Am J Med 1972;53:748–754.
Wilson HA, McLaren GD, Dworken HJ, et al. Transient pure red cell aplasia: Cell-mediated suppression of erythropoiesis associated with hepatitis. Ann Int Med 1980;92:196–198.
Margolis HS, Naiman OV. Identification of virus components in circulating immune complex isolated during hepatitis A virus infection. Hepatology 1990;11:31–37.
Canalese J, Wyke RJ, Vergani D, et al. Circulating immune complexes in patients with fulminant hepatic failure. Gut 1981;22:845–848.
Almeida JD, Waterson AP. Immune complexes in hepatitis. Lancet: 1969;8:983–988.
Livio C, Mario A. Fulminant hepatic failure. Clinical features, etiology, epidemiology, and current management. Dig Dis Sci 1991;36:775–779.
Robert A. Cytoprotection of prostaglandins. Gastroenterology 1979;77:761–767.
Stachura J, Tarnawski A, Ivey KJ, et al. Prostaglandin protection of carbon tetrachloride-induced liver cell necrosis in the rat. Gastroenterology 1981;81:211–217.
Ruwart MJ, Rush BC, Friedle NM, et al. 16-16 Dimethyl PGE2 partially prevents necrosis due to aflatoxin in rats. Gastroenterology 1982;82:1167–1169.
Stachura J, Tarnawski A, Ivey KJ, et al. 16-16 Dimethyl PGE2 protection of rat liver against acute injury by galactosamine, acetaminophen, ethanol and ANIT. Gastroenterology 1981;80:1349–1356.
Abecassis M, Falk JA, Makowka L, et al. 16-16 Dimethyl PGE2 prevents the development of fulminant hepatitis and blocks the induction of monocyte/macrophage procoagulant activity after murine hepatitis virus strain 3 infection. J Clin Invest 1987;80:881–889.
Mizoguchi Y, Tsutsui H, Miyajima K, et al. The protective effects of prostaglandinE1 in an experimental massive hepatic cell necrosis model. Hepatology 1987;7:1184–1188.
Abecassis M, Falk JA, Blendi L, et al. Treatment of fulminant hepatic failure with a continuous infusion of Prostin VR (PGEI) (abstract). Hepatology 1987;7:1104.
Morioka H. Regeneration of cirrhotic remnant liver, after partial hepatectomy, especially the relationship between insulin receptor and hepatic regeneration (in Japanese). Arch Jpn Chir 1986;55:403–414.
Mizoguchi Y, Kuboi H, Kawada N, et al. Effects of lipo-prostaglandin E1 in an experimentally induced acute hepatic failure model. Jpn J Inflammation 1990;2:115–118.
Okita K, Matsuda S, Hata K, et al. Clinical use of glucagon and insulin in therapy of fulminant hepatic failure. Gastroenterol Jpn 1979;14:453–457.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Tomida, S., Matsuzaki, Y., Nishi, M. et al. Severe acute hepatitis A associated with acute pure red cell aplasia. J Gastroenterol 31, 612–617 (1996). https://doi.org/10.1007/BF02355068
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02355068